Prelude Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Depreciation & Amortization Growth & History (PRLD)
Prelude Therapeutics's depreciation and amortization was $1.7M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.7M | −$61,000 | −3.44% |
| 2024 | 2024-12-31 | $1.8M | $603,000 | +51.58% |
| 2023 | 2023-12-31 | $1.2M | −$155,000 | −11.71% |
| 2022 | 2022-12-31 | $1.3M | $409,000 | +44.70% |
| 2021 | 2021-12-31 | $915,000 | $373,000 | +68.82% |
| 2020 | 2020-12-31 | $542,000 | $160,000 | +41.88% |
| 2019 | 2019-12-31 | $382,000 | — | — |
Prelude Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $353,000 | −$80,000 | −18.48% |
| Q1 2026 | 2026-03-31 | $391,000 | −$44,000 | −10.11% |
| Q4 2025 | 2025-12-31 | $418,000 | — | — |
| Q3 2025 | 2025-09-30 | $425,000 | $20,000 | +4.94% |
| Q2 2025 | 2025-06-30 | $433,000 | −$19,000 | −4.20% |
| Q1 2025 | 2025-03-31 | $435,000 | $9,000 | +2.11% |
| Q3 2024 | 2024-09-30 | $405,000 | $126,000 | +45.16% |
| Q2 2024 | 2024-06-30 | $452,000 | $171,000 | +60.85% |
| Q1 2024 | 2024-03-31 | $426,000 | $148,000 | +53.24% |
| Q3 2023 | 2023-09-30 | $279,000 | −$58,000 | −17.21% |
| Q2 2023 | 2023-06-30 | $281,000 | −$37,000 | −11.64% |
| Q1 2023 | 2023-03-31 | $278,000 | −$29,000 | −9.45% |
| Q3 2022 | 2022-09-30 | $337,000 | $71,000 | +26.69% |
| Q2 2022 | 2022-06-30 | $318,000 | $119,000 | +59.80% |
| Q1 2022 | 2022-03-31 | $307,000 | $147,000 | +91.88% |
| Q3 2021 | 2021-09-30 | $266,000 | $124,000 | +87.32% |
| Q2 2021 | 2021-06-30 | $199,000 | $64,000 | +47.41% |
| Q1 2021 | 2021-03-31 | $160,000 | $28,000 | +21.21% |
| Q3 2020 | 2020-09-30 | $142,000 | — | — |
| Q2 2020 | 2020-06-30 | $135,000 | — | — |
| Q1 2020 | 2020-03-31 | $132,000 | — | — |
Prelude Therapeutics depreciation and amortization trends
Over the last five fiscal years, Prelude Therapeutics's depreciation and amortization increased from $542,000 to $1.7M, a change of $1.2M. The latest reported quarter, Q2 2026, shows $353,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...